An antibiotic trident {#cesec10}
=====================

US scientists have created a vancomycin analogue they think will push back the threat of antibiotic resistance. The analogue, made by [researchers](http://dx.doi.org/10.1073/pnas.1704125114){#interrefs10} at The Scripps Research Institute in La Jolla, CA, USA, has three independent modes of action on bacterial cell wall synthesis or maintenance. It has proved effective against vancomycin-resistant strains of both enterococci and *Staphylococcus aureus* in vitro, which showed no resistance after 50 rounds of testing. The findings are preliminary, with the 30-step manufacturing process needing to be simplified before testing in animals and people.

The secret gardnerella {#cesec20}
======================

The appeal of HIV microbicide gels is that they can protect women who cannot negotiate condom use, yet gel formulations of one drug, tenofovir, have been more effective in men than in women. US [researchers](http://dx.doi.org/10.1126/science.aai9383){#interrefs20} think that this reduced efficacy is due to the composition of some women\'s vaginal microbiome. They took samples from South African women in a trial of an intravaginal tenofovir gel and found an increased risk of later HIV infection in women with predominantly *Gardnerella vaginalis* bacteria compared with those who had mostly Lactobacillus bacteria. *G vaginalis* metabolises the active form of the drug. These findings might have implications when deciding which women are offered treatment.
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Echolocating coronaviruses {#cesec30}
==========================

Findings from an international sampling study have shown that bats harbour a wide range of coronaviruses. The study, which took 5 years and spanned 20 countries in three continents, used PCR to analyse samples from 19 192 bats, rodents, non-human primates, and people in areas with the highest risk of animal-to-man transmission (areas of deforestation, ecotourism centres, and animal sanctuaries). The researchers found more than 100 different coronaviruses---98% of the animals harbouring these viruses were bats. Extrapolating from the 282 bat species in the study to the roughly 1200 species of bat worldwide, the researchers estimated that bats could harbour 3204 different coronaviruses. The findings should not prompt a bat cull, the researchers said, but should instead stimulate research into the viruses\' host ecology to reduce future epidemic risk.

HIV\'s last mile {#cesec40}
================

Research into a cure for HIV is stymied by a seemingly simple question: how do you tell if a patient is cured? The virus can lie dormant and hidden in immune cells and can begin replicating once antiretroviral treatment is stopped. The gold standard to test for such stubborn viruses is a quantitative outgrowth assay (Q-VOA), in which the virus is grown from a sample: this process needs large blood samples and is labour-intensive, time consuming, and expensive. Scientists have now developed a new [test](http://dx.doi.org/10.1038/nm.4347){#interrefs30}, called TZA, which detects a gene turned on only when the virus is replicating, taking half the time and a third of the cost of Q-VOA.

How Zika virus targets fetal brains {#cesec50}
===================================

[Scientists](http://dx.doi.org/10.1126/science.aam9243){#interrefs40} have identified a protein that the Zika virus uses to preferentially target fetal brain cells and cause microencephaly. The protein, a neural RNA-binding protein called Musashi-1 (MSI1), is essential for neuronal development, and is expressed in high concentrations in fetal brain stem cells but not in mature neurons. In cell cultures, they showed that viral replication was reduced in cells engineered not to express the protein compared with cells that do. The virus interacts with MSI1 to replicate and in so doing disrupts the protein\'s ability to bind to its endogenous targets and dysregulates neural cell development.

HIV: a hard target {#cesec60}
==================

Because HIV mutates rapidly, finding a reliable vaccine target is difficult. One potential antibody target is an envelope glycoprotein in clade C HIV, the most common subtype of the virus in sub-Saharan Africa and India. The [glycoprotein](http://dx.doi.org/10.1016/j.immuni.2017.04.014){#interrefs50} is unstable, but by re-engineering it and strengthening the interactions between its molecules scientists have managed to capture its structure with x-ray crystallography. In a companion study, they used a version of this immunogen which neutralised the clade C HIV strain in non-human primates.

Cryptic clues {#cesec70}
=============

Cryptosporidiosis is a major cause of diarrhoeal disease and death in low-income countries. There are no vaccines against the disease and the only approved treatment, nitazoanide, has poor results in infants and immunocompromised patients. Efforts to find new treatments are hindered by the fact that cryptosporidium, the protozoan parasite that causes the disease, does not last long in laboratory conditions. Using a transgenic version of the parasite that emits light and is thus easier to spot, an international team of [researchers](http://dx.doi.org/10.1038/nature22337){#interrefs60} screened 6200 potential compounds and identified a candidate drug, KDU731, that will go into pre-clinical testing.
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